Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update
Brazilian Journal of Otorhinolaryngology,
Journal Year:
2024,
Volume and Issue:
90(3), P. 101394 - 101394
Published: Jan. 30, 2024
Biologics
targeting
type
2
inflammation
have
revolutionized
the
way
we
treat
patients
with
Chronic
Rhinosinusitis
Nasal
Polyps
(CRSwNP).
Particularly
in
severe
and
difficult-to-control
cases,
these
drugs
provided
a
new
reality
for
patients,
allowing
effective
safe
treatment
of
extensive
diseases
that
were
not
completely
managed
typical
strategy
surgery
topical
medications.
The
experience
achieved
approval
medications
by
ANVISA
use
CRSwNP
knowledge
obtained
regarding
outcomes,
adverse
effects,
ideal
patient
profile
prompted
update
previously
published
guideline,
detailed
review
most
recent
scientific
literature,
personal
experiences
experts,
adaptation
to
Brazilian
healthcare
system,
both
public
private.
We
proposed
eligibility
criterion
biologics
based
on
four
pillars
indication:
impact
disease
patient's
life,
whether
presence
specific
symptoms
or
overall
quality
life;
extent
sinonasal
disease;
comorbidities,
considering
other
associated
may
also
benefit
from
anti-T2
biologics,
biomarkers
define
inflammation,
especially
those
worse
prognoses.
This
innovative
pioneering
method
has
two
major
advantages.
First,
it
ensures
comprehensive
evaluation
patients;
second,
is
flexible,
as
advancements
our
understanding
changes
cost-effectiveness
can
be
addressed
simply
adjusting
required
score
indication,
without
need
modify
entire
scheme.
Language: Английский
Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond
Journal of Asthma and Allergy,
Journal Year:
2025,
Volume and Issue:
Volume 18, P. 779 - 793
Published: May 1, 2025
Language: Английский
Asthma Phenotypes in the Era of Personalized Medicine
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(19), P. 6207 - 6207
Published: Sept. 26, 2023
Asthma
is
a
widespread
disease
affecting
approximately
300-million
people
globally.
This
condition
leads
to
significant
morbidity,
mortality,
and
economic
strain
worldwide.
Recent
clinical
laboratory
research
advancements
have
illuminated
the
immunological
factors
contributing
asthma.
As
of
now,
asthma
understood
be
heterogeneous
disease.
Personalized
medicine
involves
categorizing
by
its
endotypes,
linking
observable
characteristics
specific
mechanisms.
Identifying
these
endotypic
mechanisms
paramount
in
accurately
profiling
patients
tailoring
therapeutic
approaches
using
innovative
biological
agents
targeting
distinct
immune
pathways.
article
presents
synopsis
key
implicated
pathogenesis
manifestation
disease’s
phenotypic
traits
individualized
treatments
for
severe
subtypes.
Language: Английский
Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis
Current Allergy and Asthma Reports,
Journal Year:
2023,
Volume and Issue:
23(6), P. 287 - 298
Published: May 16, 2023
Language: Английский
Moderate asthma: burden, mechanisms and therapeutic perspectives
Current Opinion in Allergy and Clinical Immunology,
Journal Year:
2023,
Volume and Issue:
24(1), P. 32 - 36
Published: Oct. 25, 2023
Purpose
of
review
Global
Initiative
for
Asthma
(GINA)
document
provides
a
classification
asthma
severity
according
with
the
current
level
treatment
required
to
achieve
diseases
control
and
underlines
limitations
this
approach.
In
review,
we
will
provide
an
overview
recent
investigations
that
have
analyzed
clinical
molecular
features
moderate
asthma.
Recent
findings
Moderate
is
heterogeneous
in
terms
response
inhaled
pathogenetic
mechanisms
underlying
features.
Analysis
inflammatory
pathways
patients
who
do
not
disease
remission
allows
identification
patient
subgroups
may
benefit
from
specific
biological
treatments.
Summary
Scientific
progress
makes
increasingly
clear
there
are
capable
identifying
justifying
degree
The
these,
combined
development
new
pharmacological
treatments,
be
cornerstones
improving
management
its
degrees
severity.
Language: Английский
Modern trends in asthma treatment
Vnitřní lékařství,
Journal Year:
2024,
Volume and Issue:
70(8), P. 513 - 516
Published: Dec. 18, 2024
Astma
bronchiale
je
vysoce
prevalentní
respirační
onemocnění,
které
při
nedostatečné
či
neefektivní
léčbě
snižuje
kvalitu
života
pacientů.
Základem
terapie
jsou
inhalační
glukokortikoidy,
optimálně
ve
fixní
kombinaci
s
dlouhodobě
působícími
beta-2-agonisty.
V
případě
nedostatečného
efektu
možné
zvážit
navýšení
dávky
inhalačního
glukokortikoidu,
přidání
antileukotrienu
působících
anticholinergik.
Pacient
nedostatečně
kontrolovaným
astmatem
na
maximalizované
paušální
má
být
odeslán
k
precizní
diagnostice
a
úpravě
medikace
do
specializovaného
centru
pro
léčbu
obtížně
léčitelného
astmatu.
Zde
také
vyhodnocena
indikace
podání
biologické/cílené
léčby.
New Drug for Management of Severe Uncontrolled Asthma: Tezepelumab
Current Indian Science,
Journal Year:
2023,
Volume and Issue:
02
Published: Dec. 27, 2023
Abstract:
Tezepelumab
is
a
first-in-class
human
IgG2λ
monoclonal
antibody
used
to
treat
severe,
uncontrolled
asthma.
acts
by
hindering
the
action
of
thymic
stromal
lymphopoietin
(TSLP),
an
epithelial-derived
cytokine
that
triggers
immunological
response
binding
TSLP
and
thereby
preventing
its
with
receptor
complex.
has
critical
role
in
Th2
immunity
plays
important
pathogenesis
asthma
because
it
stimulates
production
Th2-associated
inflammatory
mediators,
such
as
interleukin-4,
interleukin-5,
interleukin-9,
interleukin-13.
It
first
biologic
no
phenotypic
or
biomarker
restrictions
been
approved
for
use
severe
indicated
patients
due
safety,
tolerability,
efficacy.
Adults
experienced
considerably
lower
annualised
exacerbation
rates
(AAERs)
when
administered
tezepelumab
compared
placebo.
These
preliminary
results
TSLP-induced
release
T2
mediators
may
be
reduced,
sustained
inhibition
was
maintained
over
52-week
treatment
period.
In
this
review,
we
have
summarised
various
phase
III
clinical
trials
mechanism
Language: Английский